Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD30 + status confers therapeutic sensitivity to Bendamustine, Brentuximab vedotin in patients with Hodgkin Lymphoma.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL).